Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003041 · ClinicalTrials.gov registry record · Phase 2
Pyrazoloacridine in Treating Women With Refractory Metastatic Breast Cancer
A Phase 2 study, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00003041: Completed Phase 2 study, sponsored by Ohio State University Comprehensive Cancer Center.
NCT00003041 is a Phase 2 study that has completed, run by Ohio State University Comprehensive Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003041, a Phase 2 study, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of pyrazoloacridine in treating women who have refractory metastatic breast cancer.
Interventions
- DRUG pyrazoloacridine
Trial Details
| Field | Value |
|---|---|
| Start Date | 1997-07 |
| Est. Completion | 2002-01 |
| Phase | Phase 2 |
What the finished NCT00003041 record still lists
NCT00003041 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which pyrazoloacridine is the first listed.
NCT00003041 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003041 about?
NCT00003041 is a clinical study titled "Pyrazoloacridine in Treating Women With Refractory Metastatic Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of pyrazoloacridine in treating women who have refractory metastatic breast cancer.
What is the current status of trial NCT00003041?
This trial is currently completed. It is a Phase 2 study. The study started on 1997-07. Estimated completion is 2002-01.
What interventions are being tested in trial NCT00003041?
The interventions under investigation include: pyrazoloacridine (DRUG).
Who is sponsoring clinical trial NCT00003041?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia